Orchid Pharma Limited (ORCHPHARMA.NS)
INR 793.65
(-0.92%)
INR 793.65
(-0.92%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 2.36 Billion INR | 167.09% |
| 2022 | 289.92 Million INR | 185.55% |
| 2021 | -338.89 Million INR | 32.88% |
| 2020 | -504.94 Million INR | 30.04% |
| 2019 | -721.75 Million INR | 2.01% |
| 2018 | -736.56 Million INR | 24.34% |
| 2017 | -973.54 Million INR | 82.54% |
| 2016 | -5.57 Billion INR | -73.58% |
| 2015 | -3.21 Billion INR | -6696.92% |
| 2014 | -47.26 Million INR | 94.57% |
| 2013 | -870.16 Million INR | -254.0% |
| 2012 | -245.8 Million INR | -130.99% |
| 2011 | 793.17 Million INR | -72.49% |
| 2010 | 2.88 Billion INR | -59.51% |
| 2009 | 7.12 Billion INR | 480.68% |
| 2008 | 1.22 Billion INR | -60.51% |
| 2007 | 3.1 Billion INR | 61.88% |
| 2006 | 1.91 Billion INR | 25.51% |
| 2005 | 1.52 Billion INR | 63.42% |
| 2004 | 935.34 Million INR | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q1 | 240.48 Million INR | 251.98% |
| 2023 FY | 774.36 Million INR | 167.09% |
| 2023 Q1 | 144.34 Million INR | -57.8% |
| 2023 Q2 | 238.28 Million INR | 65.08% |
| 2023 Q3 | 337.36 Million INR | 41.58% |
| 2023 Q4 | 204.98 Million INR | -39.24% |
| 2022 FY | 289.92 Million INR | 185.55% |
| 2022 Q4 | 342.04 Million INR | 137.39% |
| 2022 Q1 | -91.8 Million INR | -404.77% |
| 2022 Q2 | 58.98 Million INR | 164.25% |
| 2022 Q3 | 144.08 Million INR | 144.29% |
| 2021 Q4 | 30.12 Million INR | 148.95% |
| 2021 Q1 | -37.87 Million INR | -158.41% |
| 2021 FY | -338.89 Million INR | 32.88% |
| 2021 Q2 | -87.61 Million INR | -131.31% |
| 2021 Q3 | -61.53 Million INR | 29.76% |
| 2020 FY | -504.94 Million INR | 30.04% |
| 2020 Q4 | 64.84 Million INR | 120.14% |
| 2020 Q3 | -321.91 Million INR | -190.39% |
| 2020 Q2 | -110.85 Million INR | 65.56% |
| 2020 Q1 | -321.91 Million INR | 15.66% |
| 2019 Q1 | -244.06 Million INR | 0.0% |
| 2019 FY | -721.75 Million INR | 2.01% |
| 2019 Q4 | -381.66 Million INR | -21.46% |
| 2019 Q2 | -259.9 Million INR | -6.49% |
| 2019 Q3 | -314.22 Million INR | -20.9% |
| 2018 Q2 | -163.54 Million INR | 0.0% |
| 2018 FY | -736.56 Million INR | 24.34% |
| 2017 Q2 | -51.54 Million INR | 0.0% |
| 2017 FY | -973.54 Million INR | 82.54% |
| 2016 FY | -5.57 Billion INR | -73.58% |
| 2015 FY | -3.21 Billion INR | -6696.92% |
| 2015 Q1 | -603.14 Million INR | 0.0% |
| 2014 FY | -47.26 Million INR | 94.57% |
| 2013 Q2 | -507.68 Million INR | 0.0% |
| 2013 FY | -870.16 Million INR | -254.0% |
| 2012 Q4 | -246.59 Million INR | 0.0% |
| 2012 Q2 | -987 Thousand INR | 0.0% |
| 2012 FY | -245.8 Million INR | -130.99% |
| 2011 Q4 | 490.92 Million INR | 0.0% |
| 2011 FY | 793.17 Million INR | -72.49% |
| 2010 FY | 2.88 Billion INR | -59.51% |
| 2009 FY | 7.12 Billion INR | 480.68% |
| 2008 FY | 1.22 Billion INR | -60.51% |
| 2007 FY | 3.1 Billion INR | 61.88% |
| 2006 FY | 1.91 Billion INR | 25.51% |
| 2005 FY | 1.52 Billion INR | 63.42% |
| 2004 FY | 935.34 Million INR | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Amrutanjan Health Care Limited | 621.02 Million INR | -280.189% |
| Biofil Chemicals and Pharmaceuticals Limited | 20.65 Million INR | -11330.471% |
| Caplin Point Laboratories Limited | 7.22 Billion INR | 67.322% |
| FDC Limited | 3.03 Billion INR | 22.173% |
| Gufic Biosciences Limited | 2.89 Billion INR | 18.409% |
| Hikal Limited | 1.49 Billion INR | -58.016% |
| Ind-Swift Laboratories Limited | 2 Billion INR | -17.523% |
| IOL Chemicals and Pharmaceuticals Limited | 4.94 Billion INR | 52.226% |
| Kilitch Drugs (India) Limited | 208.05 Million INR | -1034.861% |
| Medico Remedies Limited | 277.11 Million INR | -752.012% |
| Nectar Lifesciences Limited | 3.89 Billion INR | 39.313% |
| Par Drugs and Chemicals Limited | 551.58 Million INR | -328.05% |
| RPG Life Sciences Limited | 2.29 Billion INR | -3.0% |
| Sequent Scientific Limited | - INR | -Infinity% |
| Shilpa Medicare Limited | 3.76 Billion INR | 37.232% |
| Sigachi Industries Limited | 1.47 Billion INR | -60.193% |
| Themis Medicare Limited | 1.3 Billion INR | -81.189% |
| Unichem Laboratories Limited | - INR | -Infinity% |
| Venus Remedies Limited | 534.65 Million INR | -341.611% |
| Wanbury Limited | 1.7 Billion INR | -38.301% |
| ZIM Laboratories Limited | 1.09 Billion INR | -115.012% |
| Lupin Limited | 27.75 Billion INR | 91.494% |
| Innova Captab Limited | 2.53 Billion INR | 6.802% |
| Ind-Swift Limited | 1.22 Billion INR | -92.59% |
| Bajaj HealthCare Limited | - INR | -Infinity% |
| Aurobindo Pharma Limited | 104.5 Billion INR | 97.741% |
| Solara Active Pharma Sciences Limited | -3.85 Billion INR | 161.281% |
| AstraZeneca Pharma India Limited | 4.47 Billion INR | 47.226% |
| Mangalam Drugs & Organics Limited | 27.45 Million INR | -8498.871% |
| Morepen Laboratories Limited | 4.17 Billion INR | 43.431% |
| Laurus Labs Limited | 3.94 Billion INR | 40.205% |
| Aarti Drugs Limited | 7.14 Billion INR | 66.972% |
| Glenmark Life Sciences Limited | 8.97 Billion INR | 73.705% |
| Alembic Limited | 767.77 Million INR | -207.524% |
| Alembic Pharmaceuticals Limited | 5.75 Billion INR | 58.996% |
| Glenmark Pharmaceuticals Limited | 6.5 Billion INR | 63.689% |
| Vaishali Pharma Limited | 6.29 Million INR | -37413.155% |
| Aarti Pharmalabs Limited | 3.12 Billion INR | 24.521% |
| Jagsonpal Pharmaceuticals Limited | 214.04 Million INR | -1003.101% |
| Jubilant Pharmova Limited | 5.18 Billion INR | 54.498% |
| Eris Lifesciences Limited | 5.18 Billion INR | 54.434% |
| Windlas Biotech Limited | 1.29 Billion INR | -81.777% |
| Sun Pharmaceutical Industries Limited | 104.3 Billion INR | 97.736% |
| Lincoln Pharmaceuticals Limited | 1.9 Billion INR | -23.855% |
| Albert David Limited | 1.33 Billion INR | -76.932% |
| Hester Biosciences Limited | 364.77 Million INR | -547.279% |
| Sakar Healthcare Limited | 495.5 Million INR | -376.498% |
| Suven Pharmaceuticals Limited | 4.6 Billion INR | 48.757% |
| Procter & Gamble Health Limited | 2.78 Billion INR | 15.252% |
| Divi's Laboratories Limited | 18.31 Billion INR | 87.105% |
| Mankind Pharma Limited | 40.86 Billion INR | 94.223% |
| Neuland Laboratories Limited | 5.31 Billion INR | 55.603% |
| J. B. Chemicals & Pharmaceuticals Limited | 7.54 Billion INR | 68.693% |
| Zydus Lifesciences Limited | 45.39 Billion INR | 94.798% |
| Wockhardt Limited | 140 Million INR | -1586.484% |
| Bal Pharma Limited | 214.56 Million INR | -1000.382% |
| Dr. Reddy's Laboratories Limited | 67.72 Billion INR | 96.514% |
| Bliss GVS Pharma Limited | 1.23 Billion INR | -91.801% |
| Alkem Laboratories Limited | 19.46 Billion INR | 87.868% |
| Valiant Laboratories Limited | - INR | -Infinity% |
| Ajanta Pharma Limited | 19.67 Billion INR | 88.001% |
| Bafna Pharmaceuticals Limited | 237.66 Million INR | -893.465% |
| Aarey Drugs & Pharmaceuticals Limited | 2.83 Million INR | -83305.974% |
| Granules India Limited | 6.52 Billion INR | 63.833% |
| Medicamen Biotech Limited | - INR | -Infinity% |
| Ipca Laboratories Limited | 29.59 Billion INR | 92.022% |
| Brooks Laboratories Limited | -72.25 Million INR | 3367.838% |
| Syncom Formulations (India) Limited | 249.25 Million INR | -847.269% |
| Piramal Enterprises Limited | - INR | -Infinity% |
| Torrent Pharmaceuticals Limited | 25.33 Billion INR | 90.681% |
| NATCO Pharma Limited | 25.96 Billion INR | 90.906% |
| Suven Life Sciences Limited | -1.22 Billion INR | 292.612% |
| Krebs Biochemicals & Industries Limited | - INR | -Infinity% |
| Strides Pharma Science Limited | 5.22 Billion INR | 54.819% |
| Indoco Remedies Limited | 1.52 Billion INR | -54.886% |
| Alpa Laboratories Limited | 61.51 Million INR | -3738.215% |
| Lasa Supergenerics Limited | -458 Million INR | 615.514% |
| Sun Pharma Advanced Research Company Limited | -4.11 Billion INR | 157.377% |